Assessing the potential of PROTACs as treatments for Alzheimer’s disease
PROteolysis TArgeting Chimeras (PROTACs) represent a promising class of drugs designed to degrade disease-causing proteins by leveraging the ubiquitin-proteasome system. The PROTAC field is rapidly evolving, with numerous companies and academic institutions actively developing molecules for various disease targets. However, identifying promising PROTAC candidates and navigating the complex patent landscape poses significant challenges.
Discover how our client prioritized their R&D strategy by confidently assessing the feasibility of PROTAC drugs as potential therapies for Alzheimer’s disease.
Cortellis Drug Discovery Intelligence, a trusted source of biological, chemical, pharmacological and patent data in a single platform, helped the client obtain:
- A thorough, data-driven evaluation of the development landscape.
- Rapid identification of potential patent obstacles early in the development process.
- Freedom-to-operate analysis to uncover potential licensing opportunities.
